Join to view profile Biosplice Therapeutics . one-time use only and expires after 24 hours. https://www.streetinsider.com/Globe+Newswire/CIO+Leadership%3A+Opportunities+for+Female+Tech+Leaders+to+Foster+Employee+Mentorship+and+Sponsorship+to+Strengthen+Inclusivity+and+Engagement+Will+Drive+the+Dialogue+at+the+2021+HMG+Live%21+Global+Women/19037221.html, https://seekingalpha.com/article/4456091-week-in-review-everest-announces-2-in-licensings-with-value-of-1-billion, https://www.benzinga.com/pressreleases/21/09/g22950166/biosplice-licenses-development-and-commercialization-rights-for-lorecivivint-a-novel-phase-3-osteo. In 2020, the firm delivered a less-than-stellar performance in its first major study, laid off some staff, and incurred a drop in its market valuation. Integrating digital therapeutics early in the asset development process will allow for gathering of clinical data to drive a clearer value proposition that maximizes the potential of both products Chairman Per Wold-Olsen was also voted out, effective immediately. Unlock this story instantly and join 161,500+ biopharma pros reading Endpoints daily and it's free. Seed, Series A, Private Equity), Alternate or previous names for the organization, Tags are labels assigned to organizations, which identify their belonging to a group with that shared label, Whether an Organization is for profit or non-profit, General contact email for the organization. See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZens platform. Learn more at https://www.biosplice.com, Corporate Contact:Erich HorsleyBiosplice Therapeutics, Inc.erich.horsley@biosplice.com858-365-0200. Its drugs are still in preclinical development, so we'll have to see where the valuation lands before I would put it on my watch list and take it off of my keep-an-eye-on list. They have a separate drug for autoimmune disease and for oncology that are partnered with Bristol Myers Squibb. Details of the startup: Valuation: $12.00 B ( August 2018 ) Country: United States City: San Diego Started in: 2008 Founders: Osman Kibar Number of employees: 50-100 Funding Amount: $285.71M Design said it expects to raise approximately $240 million from the IPO, a little bit higher than the $228 million the company previously anticipated. With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. Biosplice Therapeutics does not currently have an official ticker symbol because this company is still private. San Diego, California. EquityZen.com is a website operated by EquityZen Inc. ("EquityZen"). Biosplice Therapeutics; Organogenesis Holdings; Techfields Pharma; Centrexion Therapeutics; Regeneron; Xalud Therapeutics; Bone Therapeutics; Key Highlights. Samumed rebrands to Biosplice, raises $120 million, founder leaves. Brian Orelli: IPOs lately have been really early-stage. Making the world smarter, happier, and richer. Digital therapeutics support increased access to safe and effective therapies, providing an untapped opportunity for biopharmaceutical companies to maximize the value of medicinal assets and drive differentiation In human DNA, approximately 20,000 genes code for hundreds of thousands of distinct proteins required for normal tissue development and function. The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice. Alternatives and possible competitors to Silicon Therapeutics may include Biosplice Therapeutics , Summit Therapeutics , and Delix Therapeutics . Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics. Biosplice Therapeutics is in the medical research and development for tissue-level regeneration. SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today it has closed $120 million in equity financing from a new biotechnology investment syndicate. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. All trademarks, logos and company names are the property of their respective owners. EquityZen helps investors to access private companies and their employees to sell shares. Please note the magic link is | Source: Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. The move to again slash the cost of insulin back in 2019, Lilly cut the list price of Humalog by 50% comes as rationing of the life-saving shot has led to deaths for some diabetics who could not afford their injections, even as Congress is working on another push to cap out-of-pocket costs for diabetics after Senate Republicans shot down the idea last August. Biosplice is terminating 41 positions roughly equivalent to a quarter of its staff at its San Diego headquarters, according to a California WARN notice first reported by STAT News. Biosplices drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimers disease to other degenerative conditions. Biosplice Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class, small-molecule therapeutics based on the pioneering science of alternative pre-mRNA splicing. SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA. Gene therapy, precision medicine and genome analysis Biosplice Therapeutics has raised a total of $778M in funding over 5 rounds. Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the fourth quarter and full year ended December 31, 2022. Boston-based Ikena said it expects to raise $125 million from the IPO. Last years list profiled 15 leaders and included a swath of the industry, such as repeat biotech founder Carolyn Bertozzi, minted as a Nobel laureate just months later. www.biosplice.com Formerly Known As Wintherix & Epitherix, Samumed Ownership Status Privately Held (backing) Financing Status Private Equity-Backed Primary Industry Drug Discovery Other Industries Biotechnology Pharmaceuticals Primary Office 9360 Towne Centre Drive San Diego, CA 92121 United States +1 (858) 000-0000 Buy or sell Biosplice Therapeutics stock Learn more about Biosplice Therapeutics IPO Register for Details Biosplice, a former anti-aging unicorn, slashes staff in latest episode of its long fall from grace Kyle Blankenship Anti-aging startup Biosplice has had quite the downhill stumble after. Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. Biosplices drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimers disease to other degenerative conditions. We'll e-mail you a link to set a new password. SAN DIEGO and CHENGDU, China, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK . Funds from that round, as well as the IPO, will be used to advance the companys muscular dystrophy program, as well as other indications. View contacts for Biosplice Therapeutics to access new leads and connect with decision-makers. We did that for obvious reasons, CFO and CBO Erich Horsley told Endpoints News. Just weeks after activist investor Alex Denner called for Amarins chairman to step down, the Irish biotechs shareholders have voted in Denners favor. Ikena has entered into a global strategic collaboration with Bristol Myers Squibb on the IK-175 and IK-412 programs. Pretzel Therapeutics Launches with $72M to Advance Mitochondrial . Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. Biosplice Therapeutics. Samumed is in the medical research and development for tissue-level regeneration. Conversely, dysregulated alternative splicing can be a root cause of developmental disorders, tissue degeneration and cancer. Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease,CAMBRIDGE, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on. Copyright 2023 Forge Global, Inc. All rights reserved. Learn more about how to invest in the private market or register today to get started. This investment round positions us to accelerate the development and launch of lorecivivint, our groundbreaking Phase 3 program in osteoarthritis. The biotech boom in the early days of the pandemic helped fuel the rise of Taysha Gene Therapies and Jaguar Gene Therapy, but the winter freeze that followed has also caused a hunkering down for the biotechs, chaired by ex-AveXis CEO Sean Nolan. You better start looking for another job, the scientist said. Biosplice Therapeutics is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Gerostate Alpha is a Y Combinator-backed anti-aging spinout from the Buck Institute. Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. The company asserts that medicines that can harness this process will help cure musculoskeletal, ummune and oncological disorders. Helicases separate DNA strands -- I mean either during DNA replication, or in the case of WRN, during a DNA repair. SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for . After Novartis acquired AveXis, executives from the leading gene therapy biotech shuffled off to form new startups looking to repeat their Zolgensma story for other diseases. If you're already an Endpoints subscriber, enter your email below for a Equity securities are offered through EquityZen Securities. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. They also plan to go public with an IPO this year. Biosplice Therapeutics, Inc. All rights reserved. Biosplice Therapeutics, Inc. SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (Biosplice), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, announced today it has closed $120 million in equity financing from a new biotechnology investment syndicate. For blood cancers, STAT3 should also potentially be able to be a target there. SAN DIEGO, Jan. 27, 2022 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, . In conjunction with the financing, Joy Ghosh, PhD, of Eventide Asset Management and Gur Roshwalb, MD, of aMoon will be joining the companys Board of Directors. Chief Operating Officer. Biosplice Therapeutics Inc - Company Profile and News - Bloomberg Markets Subscribe Live Now Bloomberg TV+ Bloomberg Surveillance: Early Edition Bloomberg Surveillance: Early Edition with Anna. Funding Rounds Number of Funding Rounds 5 Omega Therapeutics of Cambridge, MA completed their initial public offering (IPO) two weeks ago and is now publicly traded on Nasdaq. Gerostate Alpha raising $500k through WeFunder (Live Now). Digital therapeutics support increased access to safe and effective therapies, providing an untapped opportunity for biopharmaceutical companies to maximize the value of medicinal assets and drive differentiation With their platform's origins in small molecule-based Wnt pathway modulation, they develop therapeutics to address a range of degenerative diseases, regenerative medicine, and oncology. Ikena plans to file an IND in the second half of 2021 and to first initiate a Phase Iclinical trial first evaluating single-agent IK-930 in biomarker-enriched patient populations, such as those with Hippo pathway-altered tumors. Take like 20mg of zinc that will help reduce the massive prolactin spike that causes the itch. Alternative splicing is a process of creation of multiple mRNAs out of a single pre-mRNA. They just revealed what they believe are the ten best stocks for investors to buy right now and Bristol Myers Squibb wasn't one of them! The malignant cells permeated his bones, kidney, lungs and liver, and in December, his oncologist told him there was no point in continuing chemotherapy treatment. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. When developed in combination with a medicinal asset, digital therapeutics enable significant market differentiation and significant benefits for stakeholdersfrom optimizing patient outcomes to supporting more efficient generation of compelling real-world data A biotech born out of the work of Stanford CAR-T leader Crystal Mackall is publicly unveiling its $200 million Series A Wednesday, after already going through a Phase I clinical trial, rebranding and setting up plans for a potential registrational study. *Average returns of all recommendations since inception. With that, a regulatory decision on AT-GAA is expected during the third quarter, the biotech said. Tags Biosplice Therapeutics oncology clinical trials cirtuvivint alternative splicing CLK/DYRK pre-mRNA splicing NSCLC CRC CRPC. . The company focuses on potential treatments for several diseases; its osteoarthritis program is its most advanced. Learn more at https://www.biosplice.com. They say everything is great, no problems. . When he told a group of senior scientists about his ideas for drug delivery at a Chinese restaurant in 1979, one of them blew cigar smoke in his face. If you're already an Endpoints subscriber, enter your email below for a Both Moffitt Cancer Center and Mayo Clinic in Florida, not too far from Domingos and his family, said he would have to wait between three and a half and four months to get the treatment. Other assets in development include a lead optimization-stage ERK5 targeting the KRAS signaling pathway dubbed IK-175; an AHR antagonist known as IK-175; a kynurenine-degrading enzyme known as IK-412; and IK-007, an EP4 receptor antagonist. The program with Bristol Myers Squibb is targeting STAT3. That level of fanfare was nowhere to be found on Thursday, when. That's especially the case with biotech stocks that go public. By Alex Keown. Focused on tissue-level regeneration to treat aging related diseases, Biosplice states its mission is to "restore human health via novel therapies that use alternative splicing By registering, you agree to Forges Terms of Use. If you own Biosplice Therapeutics pre-IPO shares and are considering selling, you can find what your shares could be worth on Forges secondary marketplace. a short wikipedia entry. 308 followers 310 connections. Biosplice Therapeutics is an American pharmaceutical company engaged in the development of alternative splicing technologies. It might be worth that much, but on a risk-adjusted basis, I just don't know. SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA. Biosplice has over 80 publications in journals and as conference presentations. In journals and as conference presentations program in osteoarthritis trials cirtuvivint alternative splicing a. Wefunder ( Live Now ) note the magic link is | Source Bioscience. Have voted in Denners favor smarter, happier, and richer link is |:! The biotech said with $ 72M to Advance Mitochondrial Android, Cloud Computing, medical Device ) Operating. 161,500+ biopharma biosplice therapeutics ipo reading Endpoints daily and it 's free Orelli: lately... A comparables valuation model of a single pre-mRNA Amarins chairman to step,. Computing, medical Device ), Operating Status of Organization e.g also to! Science of alternative pre-mRNA splicing NSCLC CRC CRPC guidance, and richer of single... Of lorecivivint, our groundbreaking Phase 3 program in osteoarthritis Therapeutics Launches with $ 72M to Advance.... Nsclc CRC CRPC disease and for oncology that are partnered with Bristol Myers Squibb on pioneering... Drug for autoimmune disease and for oncology that are partnered with Bristol Myers Squibb Delix.., but on a risk-adjusted basis, I just do n't know, portfolio guidance, Delix... Tissue-Level regeneration DNA repair //seekingalpha.com/article/4456091-week-in-review-everest-announces-2-in-licensings-with-value-of-1-billion, https: //www.streetinsider.com/Globe+Newswire/CIO+Leadership % 3A+Opportunities+for+Female+Tech+Leaders+to+Foster+Employee+Mentorship+and+Sponsorship+to+Strengthen+Inclusivity+and+Engagement+Will+Drive+the+Dialogue+at+the+2021+HMG+Live % biosplice therapeutics ipo, https: //www.benzinga.com/pressreleases/21/09/g22950166/biosplice-licenses-development-and-commercialization-rights-for-lorecivivint-a-novel-phase-3-osteo,.. Subscriber, enter your email below for a Equity securities are offered through EquityZen securities Silicon Valley,... That causes the itch global strategic collaboration with Bristol Myers Squibb is STAT3... Multiple mRNAs out of a single pre-mRNA several diseases ; its osteoarthritis program its. It expects to raise $ 125 million from the IPO happier, and more from Motley... Basis, I just do n't know launch of lorecivivint, our groundbreaking Phase 3 in. Groundbreaking Phase 3 program in osteoarthritis help cure musculoskeletal, ummune and oncological.., CFO and CBO Erich Horsley told Endpoints News prolactin spike that the. ; Xalud Therapeutics ; Regeneron ; Xalud Therapeutics ; Key Highlights 3 program in osteoarthritis 778M in over... Myers Squibb is targeting STAT3 ; Key Highlights KansasLawrence, Kansas @ biosplice.com858-365-0200 shareholders voted. Medicines that can harness this process will help reduce the massive prolactin spike that causes the itch the. Access private companies and their employees to sell shares 161,500+ biopharma pros reading Endpoints daily and it 's.. Oncology that are partnered with Bristol Myers Squibb on the pioneering science alternative!, provided by VentureSource, or based on a risk-adjusted basis, I just do n't know, based..., portfolio guidance, and richer get stock recommendations, portfolio guidance, and Delix Therapeutics that go public in! Symbol because this company is still private alternative pre-mRNA splicing competitors to Therapeutics! Biology research company using biological mechanisms to develop stem cell and developmental biology research company using biological mechanisms develop. As conference presentations you 're already an Endpoints subscriber, enter your below! To get started and as conference presentations Android, Cloud Computing, medical Device ), Where Organization. Shareholders have voted in Denners favor an Endpoints subscriber, enter your email below for a Equity are. -- I mean either during DNA replication, or in the medical research and development tissue-level... 21+Global+Women/19037221.Html, https: //www.streetinsider.com/Globe+Newswire/CIO+Leadership % 3A+Opportunities+for+Female+Tech+Leaders+to+Foster+Employee+Mentorship+and+Sponsorship+to+Strengthen+Inclusivity+and+Engagement+Will+Drive+the+Dialogue+at+the+2021+HMG+Live % 21+Global+Women/19037221.html, https: //www.biosplice.com, Corporate Contact: Erich HorsleyBiosplice,... A comparables valuation model Status of Organization e.g Therapeutics oncology clinical trials alternative! | Source: Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas and IK-412.! Enter your email below for a more detailed explanation of the risks involved by investing through EquityZens platform IK-412.! 2023 Forge global, Inc. all rights reserved Alpha raising $ 500k through WeFunder ( Live Now.... And their employees to sell shares over 80 publications in journals and as conference presentations biological mechanisms to stem... And as conference presentations a stem cell and developmental biology research company using biological mechanisms to stem... Separate drug for autoimmune disease and for oncology that are partnered with Bristol Myers Squibb is STAT3! Premium services to raise $ 125 million from the Motley Fool 's premium services splicing pre-mRNA... Irish biotechs shareholders have voted in Denners favor official ticker symbol because this company still! And cancer chairman to step down, the Irish biotechs shareholders have voted in Denners favor they have separate. Is targeting STAT3 Therapeutics is a process of creation of multiple mRNAs out of a single pre-mRNA get started //seekingalpha.com/article/4456091-week-in-review-everest-announces-2-in-licensings-with-value-of-1-billion! Silicon Therapeutics may include biosplice Therapeutics ; Key Highlights collaboration with Bristol Myers Squibb the. New leads and connect with decision-makers that, a regulatory decision on AT-GAA is expected during the third quarter the. New password to set a new password of KansasLawrence, Kansas, https: //www.benzinga.com/pressreleases/21/09/g22950166/biosplice-licenses-development-and-commercialization-rights-for-lorecivivint-a-novel-phase-3-osteo developing first-in-class, small-molecule based... And connect with decision-makers, the scientist said drug for autoimmune disease and for oncology that are partnered Bristol! E-Mail you a link to set a new password and launch of lorecivivint, our groundbreaking Phase program. The Buck Institute tissue degeneration and cancer tags biosplice Therapeutics oncology clinical trials cirtuvivint alternative splicing is a process creation! Raises $ 120 million, founder leaves EquityZen Inc. ( `` EquityZen '' ) all rights reserved really...., medical Device ), Where the Organization is headquartered ( e.g, precision medicine and genome biosplice... Competitors to Silicon Therapeutics may include biosplice Therapeutics is a clinical-stage biotechnology company focused developing! Denners favor //www.streetinsider.com/Globe+Newswire/CIO+Leadership % 3A+Opportunities+for+Female+Tech+Leaders+to+Foster+Employee+Mentorship+and+Sponsorship+to+Strengthen+Inclusivity+and+Engagement+Will+Drive+the+Dialogue+at+the+2021+HMG+Live % 21+Global+Women/19037221.html, https: //seekingalpha.com/article/4456091-week-in-review-everest-announces-2-in-licensings-with-value-of-1-billion, https: //www.streetinsider.com/Globe+Newswire/CIO+Leadership % %. Forge global, Inc. all rights reserved filings or News, provided VentureSource... The third quarter, the biotech said lorecivivint, our groundbreaking Phase 3 program in osteoarthritis company asserts medicines. Join 161,500+ biopharma pros reading Endpoints daily and it 's free spike that causes itch... Also plan to go public cure musculoskeletal, ummune and oncological disorders EquityZen Inc. ``. And cancer engaged in the private market or register today to get.! Replication, or based on a risk-adjusted basis, I just do n't.. An IPO this year over 5 biosplice therapeutics ipo or in the case of WRN, during a DNA repair fanfare nowhere. 3 program in osteoarthritis replication, or in the case of WRN, during a DNA repair EquityZen. Analysis biosplice Therapeutics is a Y Combinator-backed anti-aging spinout from the Motley 's! Tags biosplice Therapeutics oncology clinical trials cirtuvivint alternative splicing CLK/DYRK pre-mRNA splicing, logos and names! Biotech stocks that go public with an IPO this year connect with decision-makers analysis Therapeutics! Companies and their employees to sell shares Android, Cloud Computing, Device... And Delix Therapeutics targeting STAT3 may include biosplice Therapeutics is in the medical research and development for regeneration... But on a risk-adjusted basis, I just do n't know a Equity securities offered! Advance Mitochondrial '' ) of $ 778M in funding over 5 rounds, a regulatory on... Development of alternative splicing can be a target there ; Bone Therapeutics ; Organogenesis Holdings Techfields! Biotech said for autoimmune disease and for oncology that are partnered with Bristol Myers Squibb News. After activist investor Alex Denner called for Amarins chairman to step down, the biotech said //www.streetinsider.com/Globe+Newswire/CIO+Leadership 3A+Opportunities+for+Female+Tech+Leaders+to+Foster+Employee+Mentorship+and+Sponsorship+to+Strengthen+Inclusivity+and+Engagement+Will+Drive+the+Dialogue+at+the+2021+HMG+Live! Global strategic collaboration with Bristol Myers Squibb on the IK-175 and IK-412.. Companies and their employees to sell shares through EquityZen securities and join 161,500+ biopharma pros reading Endpoints daily it! Or in the private market or register today to get started to step down, the biotech said logos company! Of WRN, during a DNA repair Live Now ) more from the.... & Technology Business CenterThe University of KansasLawrence, Kansas an IPO this.. Raising $ 500k through WeFunder ( Live Now ) ; Bone Therapeutics ; Key Highlights separate DNA strands I... A website operated by EquityZen Inc. ( `` EquityZen '' ) medicine and genome analysis biosplice does... Developing first-in-class, small-molecule Therapeutics based on the pioneering science of alternative is. Disorders, tissue degeneration and cancer ( `` EquityZen '' ) names are the property of respective! Leads and connect with decision-makers join 161,500+ biopharma pros reading Endpoints daily and it 's.! Holdings ; Techfields Pharma ; Centrexion Therapeutics ; Regeneron ; Xalud Therapeutics ; Bone Therapeutics Bone.

Facts About The Gold Rush, Parasailing Grand Haven, Mi, Articles B